LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Kodu・Aktsiate loetelu・Ovid therapeutics Inc

Ovid therapeutics Inc

Suletud

SektorTervishoid

2.4 -7.34

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.36

Max

2.6

Põhinäitajad
By Trading Economics
Sissetulek	-27M -17M
Aktsiakasum	-0.125
Kasumimarginaal	-2,366.017
Töötajad	23
EBITDA	-5.5M -18M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+95.24% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-19M 464M
Eelmine avamishind	9.74
Eelmine sulgemishind	2.4

Uudiste sentiment

By Acuity

50%

153 / 344 Pingereas Healthcare

Ovid therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. juuni 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1. juuni 2026, 23:38 UTC

Omandamised, ülevõtmised, äriostud

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1. juuni 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1. juuni 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. juuni 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1. juuni 2026, 22:08 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. juuni 2026, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. juuni 2026, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1. juuni 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

Greg Abel's Week Is Off to Quite a Start -- WSJ

1. juuni 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1. juuni 2026, 21:22 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1. juuni 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

1. juuni 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. juuni 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1. juuni 2026, 20:46 UTC

Omandamised, ülevõtmised, äriostud

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1. juuni 2026, 20:22 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1. juuni 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1. juuni 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Declares $11 Special Div

1. juuni 2026, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1. juuni 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1. juuni 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1. juuni 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1. juuni 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1. juuni 2026, 18:54 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1. juuni 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1. juuni 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1. juuni 2026, 18:00 UTC

Omandamised, ülevõtmised, äriostud

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1. juuni 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1. juuni 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. juuni 2026, 17:10 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Ovid therapeutics Inc Prognoos

Hinnasiht

By TipRanks

95.24% tõus

12 kuu keskmine prognoos

Keskmine 5.33 USD 95.24%

Kõrge 7 USD

Madal 4 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Ovid therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Ovid therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

153 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.